X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1127) 1127
Newsletter (22) 22
Newspaper Article (12) 12
Book Chapter (11) 11
Magazine Article (8) 8
Conference Proceeding (1) 1
Dissertation (1) 1
Transcript (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
liraglutide (964) 964
science & technology (875) 875
life sciences & biomedicine (858) 858
humans (811) 811
diabetes mellitus, type 2 - drug therapy (572) 572
type 2 diabetes (525) 525
hypoglycemic agents - therapeutic use (445) 445
endocrinology & metabolism (434) 434
diabetes (432) 432
male (430) 430
female (390) 390
glucagon-like peptide 1 - analogs & derivatives (385) 385
middle aged (321) 321
hypoglycemic agents - adverse effects (275) 275
liraglutide - therapeutic use (270) 270
treatment outcome (258) 258
glucagon-like peptide 1 - therapeutic use (250) 250
glucagon (216) 216
obesity (211) 211
hypoglycemic agents - administration & dosage (204) 204
adult (203) 203
aged (201) 201
insulin (195) 195
exenatide (190) 190
clinical trials (187) 187
pharmacology & pharmacy (187) 187
diabetes mellitus, type 2 - blood (185) 185
diabetes mellitus (184) 184
drug therapy (184) 184
glucose (177) 177
animals (176) 176
blood glucose - drug effects (170) 170
analysis (169) 169
glucagon-like peptide 1 - adverse effects (165) 165
care and treatment (163) 163
peptides (157) 157
risk factors (151) 151
diabetes therapy (144) 144
blood glucose - metabolism (143) 143
liraglutide - adverse effects (142) 142
internal medicine (137) 137
peptides - therapeutic use (137) 137
liraglutide - administration & dosage (135) 135
hypoglycemic agents - pharmacology (132) 132
research (132) 132
obesity - drug therapy (129) 129
general & internal medicine (125) 125
venoms - therapeutic use (123) 123
double-blind method (122) 122
glucagon-like peptide 1 - administration & dosage (122) 122
body weight (121) 121
weight loss - drug effects (119) 119
medicine, general & internal (118) 118
weight loss (117) 117
glycated hemoglobin a - metabolism (116) 116
drug therapy, combination (115) 115
glucagon-like peptide-1 receptor (115) 115
glucagon-like peptide-1 receptor - agonists (113) 113
body mass index (112) 112
dosage and administration (111) 111
hypoglycemic agents (110) 110
glp-1 (106) 106
health aspects (106) 106
hypoglycemia (106) 106
liraglutide - pharmacology (104) 104
glucagon-like peptide 1 (103) 103
receptors, glucagon - agonists (101) 101
diabetes mellitus, type 2 - complications (99) 99
patients (99) 99
abridged index medicus (98) 98
medicine & public health (97) 97
type 2 diabetes mellitus (94) 94
dextrose (92) 92
glycosylated hemoglobin (88) 88
body weight - drug effects (87) 87
original (87) 87
diabetes mellitus, type 2 - metabolism (86) 86
drug administration schedule (85) 85
metformin (83) 83
glucagon-like peptide 1 - pharmacology (82) 82
glycated hemoglobin a - analysis (81) 81
randomized controlled trials as topic (81) 81
incretins - therapeutic use (80) 80
weight control (78) 78
blood pressure (77) 77
hypoglycemia - chemically induced (77) 77
metformin - therapeutic use (75) 75
endocrinology (71) 71
medicine, research & experimental (71) 71
research & experimental medicine (71) 71
diabetes mellitus, type 2 - physiopathology (70) 70
sitagliptin (70) 70
medical research (69) 69
dipeptidyl-peptidase iv inhibitors - therapeutic use (68) 68
insulin resistance (67) 67
complications and side effects (65) 65
peptides - adverse effects (65) 65
glucagon-like peptide-1 (64) 64
original article (64) 64
anti-obesity agents - therapeutic use (63) 63
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1150) 1150
German (12) 12
Japanese (6) 6
Spanish (6) 6
French (4) 4
Chinese (3) 3
Italian (2) 2
Portuguese (2) 2
Danish (1) 1
Dutch (1) 1
Hungarian (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Scientific reports, ISSN 2045-2322, 01/2016, Volume 6, Issue 1, pp. 18904 - 18904
A meta-analysis was conducted to assess the clinical efficacy and safety of dulaglutide in patients with type 2 diabetes mellitus (T2DM). Medline, Embase,... 
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Glycated Hemoglobin A - metabolism | Humans | Body Weight - drug effects | Immunoglobulin Fc Fragments - administration & dosage | Insulin - blood | Metformin - adverse effects | Peptides - administration & dosage | Insulin Glargine - administration & dosage | Hypoglycemic Agents - administration & dosage | Hypoglycemia - physiopathology | Patient Safety | Venoms - administration & dosage | Hypoglycemia - blood | Metformin - administration & dosage | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Sitagliptin Phosphate - administration & dosage | Insulin Glargine - adverse effects | Venoms - adverse effects | Treatment Outcome | Randomized Controlled Trials as Topic | Glucagon-Like Peptides - adverse effects | Diabetes Mellitus, Type 2 - blood | Diabetes Mellitus, Type 2 - physiopathology | Hypoglycemia - etiology | Liraglutide - adverse effects | Liraglutide - administration & dosage | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Peptides - adverse effects | Sitagliptin Phosphate - adverse effects | Diabetes mellitus | Body weight | Clinical trials | Body weight loss | Diabetes | Metformin | Hypoglycemia | Insulin | Index Medicus
Journal Article
Endocrine, ISSN 1559-0100, 11/2016, Volume 57, Issue 3, pp. 464 - 473
To compare the effect of liraglutide, sitagliptin and insulin glargine added to standard therapy on left ventricular function in post-ischemic type-2 diabetes mellitus... 
Type 2 diabetes | Glucagon-like peptide-1 | Medicine & Public Health | Science, Humanities and Social Sciences, multidisciplinary | Left ventricular ejection fraction | Cardiac function | Internal Medicine | Diabetes | Chronic heart failure | Endocrinology | Liraglutide | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Metformin - therapeutic use | Diabetic Cardiomyopathies - drug therapy | Humans | Middle Aged | Heart Failure - physiopathology | Ventricular Dysfunction, Left - complications | Male | Heart Failure - blood | Diabetic Cardiomyopathies - physiopathology | Metformin - adverse effects | Cardiotonic Agents - therapeutic use | Hypoglycemia - prevention & control | Drug Therapy, Combination - adverse effects | Ventricular Dysfunction, Left - blood | Cardiotonic Agents - adverse effects | Female | Diabetic Cardiomyopathies - blood | Diabetes Mellitus, Type 2 - complications | Heart - physiopathology | Hypoglycemic Agents - therapeutic use | Heart Failure - complications | Hyperglycemia - prevention & control | Insulin Glargine - adverse effects | Sulfonylurea Compounds - therapeutic use | Insulin Glargine - therapeutic use | Stroke Volume - drug effects | Biomarkers - blood | Sulfonylurea Compounds - adverse effects | Ventricular Dysfunction, Left - physiopathology | Heart Failure - drug therapy | Diabetes Mellitus, Type 2 - blood | Pilot Projects | Ventricular Dysfunction, Left - drug therapy | Liraglutide - adverse effects | Incretins - adverse effects | Liraglutide - therapeutic use | Heart - drug effects | Quality of Life | Sitagliptin Phosphate - therapeutic use | Aged | Incretins - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Sitagliptin Phosphate - adverse effects | Heart failure | Usage | Care and treatment | Electrocardiogram | Electrocardiography | Dosage and administration | Index Medicus
Journal Article
Diabetes, obesity & metabolism, ISSN 1462-8902, 04/2017, Volume 19, Issue 4, pp. 524 - 536
..., with the primary goal of achieving individualized glycaemic targets whilst minimizing adverse effects, particularly weight gain and hypoglycaemia. Glucagon‐like peptide‐1... 
GLP‐1 analogue | type 2 diabetes | network meta‐analysis | systematic review | network meta-analysis | GLP-1 analogue | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Glucagon-Like Peptide 1 - administration & dosage | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Humans | Middle Aged | Glycated Hemoglobin A - drug effects | Male | Immunoglobulin Fc Fragments - administration & dosage | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Venoms - administration & dosage | Female | Hypoglycemia - chemically induced | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Drug Administration Schedule | Glucagon-Like Peptide 1 - analogs & derivatives | Venoms - adverse effects | Treatment Outcome | Randomized Controlled Trials as Topic | Blood Glucose - drug effects | Glucagon-Like Peptides - adverse effects | Diabetes Mellitus, Type 2 - blood | Liraglutide - adverse effects | Incretins - adverse effects | Liraglutide - administration & dosage | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Glucagon-Like Peptide-1 Receptor - agonists | Incretins - administration & dosage | Peptides - adverse effects | Type 2 diabetes | Glycosylated hemoglobin | Glucagon | Analysis | Diabetes therapy | Hypoglycemia | Diabetes | Systematic review | Evidence-based medicine | Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 10/2014, Volume 384, Issue 9951, pp. 1349 - 1357
Journal Article
Contemporary Clinical Trials, ISSN 1551-7144, 2011, Volume 32, Issue 3, pp. 324 - 332
... diabetes drugs [2] and more recently to recommend a risk assessment and mitigation strategy for rosiglitazone [3] . An immediate effect of the guidelines was a pathway... 
Hematology, Oncology and Palliative Medicine | Cardiovascular | Saxagliptin and liraglutide | Sitagliptin | Alogliptin | Vildagliptin | Insulin inhalation powder | Exenatide | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Triazoles - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | United States | Humans | Pyrrolidines - adverse effects | Allylamine - adverse effects | Randomized Controlled Trials as Topic - standards | Time Factors | Investigational New Drug Application - legislation & jurisprudence | Sitagliptin Phosphate | Incretins - chemistry | Colesevelam Hydrochloride | Incretins - physiology | United States Food and Drug Administration | Adamantane - adverse effects | Adamantane - analogs & derivatives | Glucagon-Like Peptide 1 - analogs & derivatives | Venoms - adverse effects | Dipeptides - adverse effects | Allylamine - analogs & derivatives | Uracil - adverse effects | Piperidines - adverse effects | Pyrazines - adverse effects | Cardiovascular Diseases - chemically induced | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Nitriles - adverse effects | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Liraglutide | Peptides - adverse effects | Practice Guidelines as Topic | Uracil - analogs & derivatives | Type 2 diabetes | Hypoglycemic agents | Drug therapy | Cardiovascular diseases | Drug approval | Risk factors | Diabetes therapy | Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2009, Volume 374, Issue 9683, pp. 39 - 47
Journal Article
Diabetes, obesity & metabolism, ISSN 1462-8902, 08/2014, Volume 16, Issue 8, pp. 673 - 688
Journal Article